Loading clinical trials...
Loading clinical trials...
Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery
Conditions
Interventions
Nepafenac Ophthalmic Suspension, 0.3%
Nepafenac vehicle
+1 more
Start Date
June 1, 2013
Primary Completion Date
May 1, 2015
Completion Date
May 1, 2015
Last Updated
August 3, 2016
NCT07452770
NCT06979752
NCT07362043
NCT06060041
NCT07325188
NCT07305987
Lead Sponsor
Alcon Research
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions